Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke
2010

Efficacy and Safety of Cerebrolysin in Hemorrhagic Stroke Patients

Sample size: 100 publication Evidence: low

Author Information

Author(s): Bajenaru O, Tiu C, Moessler H, Antochi F, Muresanu D, Popescu BO, Novak P

Primary Institution: University Hospital Bucharest

Hypothesis

The study aims to investigate the efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.

Conclusion

Cerebrolysin treatment is safe and well tolerated in patients with hemorrhagic stroke, although no statistically significant efficacy was demonstrated.

Supporting Evidence

  • 96 out of 100 randomized patients completed the study.
  • The treatment was administered for 10 days with daily infusions.
  • Safety evaluations showed no significant toxic effects from Cerebrolysin.
  • Adverse events were comparable between the Cerebrolysin and placebo groups.
  • Statistical analysis indicated no significant differences in efficacy measures.

Takeaway

This study tested a medicine called Cerebrolysin to see if it helps people who have a type of stroke called hemorrhagic stroke, and it found that the medicine is safe to use.

Methodology

The study was a prospective, randomized, double-blind, placebo-controlled trial with 100 patients, assessing efficacy through various neurological scales over 21 days.

Limitations

The study did not find statistically significant group effects, and a larger sample size may be needed to provide clearer evidence of efficacy.

Participant Demographics

The study included 100 patients aged 40 to 85, with 62% male and 28% female participants, average age 65.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication